Mucin-1: a promising pan-cancer therapeutic target
Abstract Mucin1 or MUC1 (also known as CD227, EMA, MCD, MAM6, PEM, PUM, KL-6, CA 27.29/CA 15-3) is a highly glycosylated transmembrane mucin family member protein that is overexpressed in various solid or hematological cancers. Abnormal MUC1 expression/glycosylation in cancer leads to the activation...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-01016-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract Mucin1 or MUC1 (also known as CD227, EMA, MCD, MAM6, PEM, PUM, KL-6, CA 27.29/CA 15-3) is a highly glycosylated transmembrane mucin family member protein that is overexpressed in various solid or hematological cancers. Abnormal MUC1 expression/glycosylation in cancer leads to the activation of multiple pathways, resulting in tumor migration, invasion and accelerated growth. CA 27.29/CA 15-3 are blood tumor markers used in breast cancer patients. Novel therapeutic agents targeting MUC1, including cancer vaccines, cellular therapies, radiopharmaceuticals, monoclonal antibodies and antibody-drug conjugates, are being explored in clinical studies. The current review summarizes the molecular mechanisms of MUC1 in cancer and highlights existing data for MUC1-targeting agents in the therapeutic pipeline. |
|---|---|
| ISSN: | 2397-768X |